Benefits of lifestyle modification in NAFLD
- PMID: 17911352
- PMCID: PMC2095707
- DOI: 10.1136/gut.2006.112094
Benefits of lifestyle modification in NAFLD
Conflict of interest statement
Competing interests: CPD has acted as a consultant for several pharmaceutical companies interested in developing drugs for the treatment of fatty liver disease: Sanofi‐Aventis, Astellas and Pfizer. SAH has acted as a consultant for several pharmaceutical companies interested in developing drugs for the treatment of non‐alcoholic fatty liver disease: Sanofi‐Aventis and Schering‐Plough.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources